A Study comparing Savolitinib plus Osimertinib vs Savolitinib plus Placebo in Patients with EGFRm+ and MET Amplified Advanced NSCLC

Trial Identifier: D5084C00009
Sponsor: AstraZeneca
NCTID:: NCT04606771
Start Date: September 2020
Primary Completion Date: December 2022
Study Completion Date: December 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish (Argentina) Translation
Hindi Translation
Thai Translation
Vietnamese Translation
Taiwan (Traditional Chinese) Translation

Trial Locations

Country Location
AR Buenos Aires, AR, C1426ANZ
AR Buenos Aires, AR, C1120AAT
AR CABA, AR, C1012AAR
AR CABA, AR, C1431FWO
AR La Plata, AR, 1900
BR Belo Horizonte, BR, 30110-022
BR Fortaleza, BR, 60430-230
BR Porto Alegre, BR, 90035-003
BR Porto Alegre, BR, 90050-170
BR Ribeirão Preto, BR, 14015-130
BR Rio de Janeiro, BR, 22281-100
BR São Paulo, BR, 01308-050
BR São Paulo, BR, 04501-000
BR Vitoria, BR, 29043-260
CL Santiago, CL, 7520349
CL Santiago, CL, 7500713
CL Santiago, CL, 8420383
IN Bangalore, IN, 560068
IN Delhi, IN, 110085
IN Mumbai, IN, 400053
KR Daegu, KR, 41404
KR Jeonnam, KR, 58128
KR Seoul, KR, 143-729
KR Seoul, KR, 08308
KR Yangsan-si, KR, 50612
TH Bangkok, TH, 10330
TH Bangkok, TH, 10400
TH Bangkok, TH, 10700
TH Bangkok, TH, 10300
TH Bangkok, TH, 10210
TH Hat Yai, TH, 90110
TH Khon Kaen, TH, 40002
TH Muang, TH, 50200
TW Taichung City, TW, 402
TW Taipei, TW, 235
TW Taipei, TW, 11217
TW Taipei, TW, 100
TW Taoyuan City, TW, 333
US, CA Duarte, CA, US, 91010
US, CA La Jolla, CA, US, 92093
US, CA Sacramento, CA, US, 95817
US, NY Brooklyn, NY, US, 11220
VN Ha Noi, VN, 100000
VN Hanoi, VN, 100000
VN Ho Chi Minh city, VN, 700000